Journal of Comparative Effectiveness Research | Becaris Publishing

background gradient

Submit an article For Authors Sign up for Alerts Visit The Evidence Base

Open Access
Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review
- Marie A-C Neumann,
- Jonas Jost,
- Sybille Riou,
- Stefanie Rungaldier,
- Stefan Walzer, and
- Jörg Mahlich
26 Jun 2026
Open Access
Acthar Gel treatment in patients with rheumatoid arthritis, systemic lupus erythematosus, or dermatomyositis/polymyositis: analysis of physician-reported charts
- Kyle Hayes,
- Amit Patel,
- Priyanka P Shanbhag,
- Destri R Evans,
- Mary Prince Panaccio,
- Johanna Purcell, and
- George J Wan
25 Jun 2026
Open Access
Use of intracardiac echocardiography and three-dimensional mapping during catheter ablation for atrial fibrillation is associated with reduced complications: a retrospective analysis of United States Medicare Fee-For-Service Database
- Yiran Rong,
- Tom Wei,
- Kevin Corriveau, and
- Rahul Khanna
22 Jun 2026
Open Access
Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison
- Handrean Soran,
- Asia Sikora Kessler,
- Montserrat Vera-Llonch,
- Veronica J Alexander,
- Paul Serafini,
- Divya Pushkarna,
- Elisabete Rodrigues,
- Erik Stroes,
- Ulrike Schatz,
- Ursula Kassner,
- Zalmai Hakimi,
- Aletta Falk, and
- Koo Wilson
19 Jun 2026

background gradient

Now fully Open Access

Submit an Article

Free Access
Framework and guidance for implementing patient-reported outcomes in clinical practice: evidence, challenges and opportunities
- Ian Porter,
- Daniela Gonçalves-Bradley,
- Ignacio Ricci-Cabello,
- Chris Gibbons,
- Jaheeda Gangannagaripalli,
- Ray Fitzpatrick,
- Nick Black,
- Joanne Greenhalgh, and
- Jose M Valderas
18 Jul 2016
Open Access
Gene therapy: evidence, value and affordability in the US health care system
- Grace Hampson,
- Adrian Towse,
- Steven D Pearson,
- William B Dreitlein, and
- Chris Henshall
16 Nov 2017
Open Access
Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries
- Bertalan Németh,
- Anett Molnár,
- Sándor Bozóki,
- Kalman Wijaya,
- András Inotai,
- Jonathan D Campbell, and
- Zoltán Kaló
15 Feb 2019
Open Access
A 90-day episode-of-care cost analysis of robotic-arm assisted total knee arthroplasty
- Christina L Cool,
- David J Jacofsky,
- Kelly A Seeger,
- Nipun Sodhi, and
- Michael A Mont
28 Jan 2019
Open Access
Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study
30 Jan 2020
Open Access
Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
- Victoria Allan,
- Sreeram V Ramagopalan,
- Jack Mardekian,
- Aaron Jenkins,
- Xiaoyan Li,
- Xianying Pan, and
- Xuemei Luo
18 Mar 2020
Free Access
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement
- Patricia A Deverka,
- Danielle C Lavallee,
- Priyanka J Desai,
- Laura C Esmail,
- Scott D Ramsey,
- David L Veenstra, and
- Sean R Tunis
5 Mar 2012
Open Access
Evaluating patient and stakeholder engagement in research: moving from theory to practice
- Laura Esmail,
- Emily Moore, and
- Alison Rein
31 Mar 2015

Open Access
The need to consider market access for pharmaceutical investment decisions: a primer
- Sreeram V Ramagopalan,
- Catherine Bacon,
- Mel Walker, and
- Michael L Ryan
4 Apr 2025
Free Access
Early mobilization in enhanced recovery after surgery pathways: current evidence and recent advancements
- Reeana Tazreean,
- Gregg Nelson, and
- Rosie Twomey
20 Jan 2022
Open Access
How much do ex-US revenues make a difference for pharmaceutical investment returns?
- Sreeram V Ramagopalan,
- Harshal Thaker,
- Mel Walker, and
- Om Narasimhan
2 Sep 2025
Open Access
Why is the market design for innovative pharmaceuticals not well understood?
- Francisco Olivença,
- Jose Diaz,
- Sreeram V Ramagopalan, and
- Louis P Garrison
10 Sep 2024
Open Access
Access in all areas? A round-up of developments in market access and health technology assessment: part 14
- Sreeram V Ramagopalan and
- Annie Jullien Pannelay
26 Mar 2026
Open Access
Access in all areas? A round-up of developments in market access and health technology assessment: part 10
- Sreeram V Ramagopalan and
- Annie Jullien Pannelay
16 Sep 2025
Open Access
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 24
- Paul Arora and
- Sreeram V Ramagopalan
9 Feb 2026
Open Access
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 23
- Paul Arora and
- Sreeram V Ramagopalan
15 Dec 2025